(75) lnspiremd, (76) Medronic, (77) Respicardia, (78) Silena Therapeutics, (79) Spectrum Sleep research, (70) Astellas, (71) Theradex, (72) Galena Biopharma, (73) Chiltern, (74) PRAint, Ud, (67) Accovion, (68) AIO: Arbeitsgemeinschaft Internistische Onkologie, (69) ASR Advanced (Sponsoring eines Workshops), (64) Seattle Geneties, (65) Symphogen, (66) TauRx Therapeuties
Mologen, (59) Nuvisan, (60) Pluristem, (61) Quintiles, (62) Roehe, (63) SehumaeherGmbH Research Organisation), (54) Jansen, (55) LUX Bioseienees, (56) MedPass, (57) Merek, (58) USA, (50) Ganymed, (51) Gilead Sciences, (52) GlaxoSmithKline, (53) ICON (Clinical (37) Zukunftsfond Berlin (TSB), (38) Amgen, (39) AO Foundation, (40) BARD, (41) BBraun, (42)īoehring Ingelheimer, (43) Brainsgate, (44) PPD (Clinical Research Organisation), (45)ĬELLACT Pharma, (46) Celgene, (47) CeloNova Bio-Sciences, (48) Covance, (49) DC Deviees, Philipps, (29) Sanofis-Aventis S.A., (30) Siemens, (31) Spectranetics GmbH, (32) Terumo MedicalĬorporation, (33) TNS Healthcare GMbH, (34) Toshiba, (35) UCB Pharma, (36) Wyeth Pharma, (25) Parexel Clinical Research Organisation Service, (26) Perceptive, (27) Pfizer GmbH, (28) (21) Lundbeck GmbH, (22) MeVis Medical Solutions AG, (23) Nexus Oncology, (24) Novartis, Research, (17) lnSightec Ud, (18) IPSEN Pharma, (19) Kendlel MorphoSys AG, (20) Lilly GmbH, Stiftungįür Herzforschung, (10) Essex Pharma, (11) EU Programmes, (12) FibrexMedical Inc, (13)įocused Ultrasound Surgery Foundation, (14) Fraunhofer Gesellschaft, (15) Guerbet, (16) INC Myers Squibb, (7) Charite Research Organisation GmbH, (8) Deutsche Krebshilfe, (9) Dt. Pharmaceuticals, (3) Bayer Schering Pharma, (4) Bayer Vital, (5) BRACCO Group, (6) Bristol Universitätsmedizin Berlin from the following companies and institutions: (1) Abbott, (2) Actelion Hamm has received research grants for the Department of Radiology, Charité CT-based quantification of visceral adipose tissue and upper abdominal circumference in routinely acquired chest CTs may therefore be a simple tool for risk assessment in SARS-CoV-2-patients. “In Ockham’s continuing progression toward building the top niche oncology CRO, joining with Chilton has been an easy choice, allowing us to leverage Chiltern’s global reach and highly developed staffing business in Europe, both of which are complementary to Ockham’s deep oncology experience and source business in the US,” said Baker.CONCLUSIONS Our results suggest that visceral adipose tissue and upper abdominal circumference specifically increasing the risk of COVID-19 severity. Baker, will become Chief Development Officer. The goal of the merger is to strengthen the new company’s position as a CRO with extensive oncology capabilities, to create a more powerful biopharmaceuticals division and to establish Chiltern as a Global Functional Service Provider (FSP).Ĭhiltern’s CEO Jim Eisenhart, PhD, will become the CEO of the newly established Chiltern Group, while Ockham’s CEO, James V. Ockham will be merged into Chiltern the new company will retain the name Chiltern.The goal of the acquisition is to bolster Chiltern’s position in oncology, biopharmaceutical development and sourcing.Chiltern, a UK-based contract research organization (CRO), has acquired 100% of North Carolina-based Ockham, also a CRO.
0 kommentar(er)
